| Literature DB >> 30858715 |
María A Trak-Fellermeier1, Maribel Campos1, Marytere Meléndez1, Jeremy Pomeroy2, Cristina Palacios3, Juana Rivera-Viñas4, Keimari Méndez4, Irma Febo5, Walter Willett6, Mathew W Gillman7, Paul W Franks6,8, Kaumudi Joshipura1,9.
Abstract
BACKGROUND: Inappropriate gestational weight gain (GWG) has been associated with adverse perinatal events. High rates of GWG have been reported among Hispanic women. Observational studies indicate that dietary and physical activity interventions during the prenatal period may improve maternal and infant health, but very few randomized trials have been conducted among high-risk overweight/obese Hispanic women. Accordingly, we conducted a lifestyle intervention among high-risk pregnant women and evaluated its impact on achieving appropriate GWG and on improving birthweight.Entities:
Keywords: birthweight; gestational weight gain; intervention; lifestyle modification; neonatal; obese; overweight; pregnancy; randomized controlled trial
Year: 2019 PMID: 30858715 PMCID: PMC6385743 DOI: 10.2147/DMSO.S179009
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Study exclusions by eligibility criteria
| Consortium exclusion criteria | N | % |
|---|---|---|
|
| ||
| Gestational age >15 weeks, 6 days | 802 | 68.2 |
| BMI (kg/m2) <25 | 138 | 11.7 |
| Age <18 years | 85 | 7.2 |
| HbA1c (%) ≥6.5 | 61 | 5.2 |
| Known fetal anomaly | 0 | 0 |
| Intention to deliver outside the LIFE-Moms | 28 | 2.4 |
| Consortium hospital Contraindication to aerobic exercise | 19 | 1.5 |
| History of ≥3 consecutive first trimester miscarriages | 10 | 0.9 |
| Unwilling to commit to a 1-year follow-up | 8 | 0.7 |
| Current use of exclusionary medications | 7 | 0.6 |
| Nonviable pregnancy | 7 | 0.6 |
| Multiple pregnancy | 4 | 0.3 |
| Prior or planned bariatric surgery | 2 | 0.2 |
| History of anorexia/bulimia | 1 | 0.1 |
| Current eating disorder | 1 | 0.1 |
| Actively suicidal | 1 | 0.1 |
| Participation in another interventional study | 1 | 0.1 |
| Past or current intravenous drug user | 1 | 0.1 |
| Self-reported HIV infection | 0 | 0 |
| Inability to fulfill study requirements | 0 | 0 |
| Not Spanish speaking | 0 | 0 |
| Plan on giving up infant for adoption | 0 | 0 |
| 1,176 | 100 | |
Notes:
Calculated from last menstrual period date reported and earliest ultrasound data;
Assessed by the Beck Depression Inventory II;
Confirmed from medical records or baseline test;
Inability to functionally participate in group sessions and other study requirements on a regular basis.
Abbreviations: BMI, body mass index; LIFE-Moms, Lifestyle Interventions for Expectant Moms.
Figure 1PEARLS recruitment, exclusions and status of enrolled participants.
Notes: *Other reasons for exclusion: 18 potential eligible women pending at the time of enrollment discontinuation and 1 lost contact during the prescreening phase.
Abbreviation: PEARLS, Pregnancy and EARly Lifestyle improvement Study.
Baseline characteristics
| Overall | Control | Intervention | |
|---|---|---|---|
| N=31 | N=16 | N=15 | |
| Mean ± SD / n (%) | |||
| Maternal age, years | 27.7±5.5 | 25.6±4.8 | 30.0±5.3 |
| Educational level | |||
| High school education/diploma or less | 15 (48.4) | 8 (50.0) | 7 (46.7) |
| College education | 16 (51.6) | 8 (50.0) | 8 (53.3) |
| Total annual family income | |||
| ≤$9,999 | 14 (45.2) | 8 (50.0) | 6 (40.0) |
| $10,000–$19,999 | 11 (35.4) | 5 (31.2) | 6 (40.0) |
| ≥$20,000 | 6 (19.4) | 3 (18.8) | 3 (20.0) |
| Any supplementary food program | 24 (77.4) | 13 (81.3) | 11 (73.3) |
| WIC | 22 (71.0) | 11 (68.8) | 11 (73.3) |
| Marital status | |||
| Married or living with a partner | 24 (77.4) | 14 (87.5) | 10 (66.7) |
| Single/separated/divorced/widowed | 7 (22.6) | 2 (12.5) | 5 (33.3) |
| Race | |||
| Black/African American | 8 (25.8) | 1 (6.3) | 7 (46.7) |
| White | 7 (22.6) | 6 (37.5) | 1 (6.6) |
| Other | 16 (51.6) | 9 (56.2) | 7 (46.7) |
| Hispanic/Latina ethnicity | 31 (100.0) | 16 (100.0) | 15 (100.0) |
| Current smoking | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Any alcohol intake during pregnancy | 1 (3.2) | 0 (0.0) | 1 (6.7) |
| Level of depressive symptoms (BDI-II) | |||
| Minimal (0–13 points) | 24 (77.4) | 12 (75.0) | 12 (80.0) |
| Mild–moderate (≥14–28 points) | 7 (22.6) | 4 (25.0) | 3 (20.0) |
| Enrollment weight (kg) | 91.4±20.8 | 92.6±19.7 | 90.1±22.5 |
| Enrollment BMI (kg/m2) | 35.3±7.4 | 36.0±7.0 | 34.6±8.0 |
| Enrollment BMI status | |||
| Overweight | 9 (29.0) | 2 (12.5) | 7 (46.7) |
| Obese | 22 (71.0) | 14 (87.5) | 8 (53.3) |
| Gestational age at enrollment (weeks, days): Median (Minimum/Maximum) | 14,4 (10,4/16,0) | 14,5 (10,6/15,6) | 14,4 (10,4/16,0) |
| Parity | |||
| Primiparous | 9 (29.0) | 5 (31.2) | 4 (26.7) |
| Multiparous | 22 (71.0) | 11 (68.8) | 11 (73.3) |
| Blood pressure at screening (mmHg) | |||
| Systolic | 114.0±12.0 | 115.5±13.2 | 112.4±10.9 |
| Diastolic | 68.8±10.6 | 67.4±9.3 | 70.2±12.0 |
| Fasting blood glucose mg/dL | 92.5±6.4 | 90.5±4.5 | 94.7±7.5 |
| Prior hypertension diagnoses with antihypertensive medication use | 6 (19.4) | 3 (18.8) | 3 (20.0) |
| Prior gestational diabetes mellitus | 2/37 (5.4) | 1/13 (7.7) | 1/24 (4.2) |
| Total energy intake (kcal/d), n=28 | 2,473±876 | 2,523±945 | 2,415±824 |
| Physical activity (VMU/min),d,e n=28 | 7,389±3,283 | 7,773±3,373 | 6,946±3,252 |
Notes: Participants with a plausible total energy intake (>1,075 kcal and <4,800 kcal) were included.
WIC: The Special Supplemental Nutrition Program for Women, Infants, and Children;
BDI-II: Beck Depression Inventory II.
Denominator includes all previous pregnancies in the studied sample,
from wrist-worn ActiGraph GT3X+.
Vector magnitude averaged over total awake time.
Abbreviations: BMI, body mass index; WIC, Women, Infants, and Children.
GWG (classified as appropriate/inappropriate by IOM guidelines) and maternal and neonatal adiposity measurements
| Outcome variables | Control mean | Intervention, mean | Unadjusted IRR (95% CI) | Model 1, adjusted IRR (95% CI) | Model 2, adjusted IRR (95% CI) | Model 3, adjusted IRR (95% CI) |
|---|---|---|---|---|---|---|
|
| ||||||
|
| ||||||
| Appropriate weekly GWG: baseline to 36 weeks (n=31) | 3 (18.8) | 4 (26.7) | 1.42 (0.32, 6.35) | 1.03 (0.20, 5.30) | 1.51 (0.31, 7.45) | 1.14 (0.20, 6.67) |
| Appropriate weekly GWG: baseline to delivery (n=31) | 2 (12.5) | 4 (26.7) | 2.13 (0.39, 11.65) | 1.04 (0.17, 6.49) | 2.20 (0.37, 13.29) | 1.14 (0.15, 8.91) |
| Appropriate total GWG: baseline to delivery (n=31) | 4 (25.0) | 6 (40.0) | 1.60 (0.45, 5.67) | 1.59 (0.40, 6.33) | 1.69 (0.44, 6.48) | 1.67 (0.40, 6.94) |
|
| ||||||
|
| ||||||
|
| ||||||
| Neck | 0.64±1.35 | 0.16±1.18 | −0.48 (−1.64, 0.67) | −0.11 (−1.32, 1.11) | −0.53(−1.75, 0.68) | −0.09 (−1.42, 1.24) |
| Arm | −0.09±2.62 | −0.50±2.65 | −0.40 (−2.76, 1.95) | −0.13 (−2.75, 2.50) | −0.75 (−3.14, 1.65) | −0.62 (−3.39, 2.15) |
| Thigh | 1.98±4.29 | −1.29±2.60 | −3.27 (−6.61, 0.06) | |||
| Hip | 4.14±5.33 | 7.47±7.81 | 3.33 (−2.40, 9.07) | 3.45 (−2.99, 9.89) | 3.93 (−2.02, 9.88) | 4.47 (−2.41, 11.34) |
|
| ||||||
| 38,4 (34,1/41,1) | 37,5 (26,4/40,0) | – | – | – | – | |
|
| ||||||
|
| ||||||
|
| ||||||
| All | −0.05±1.26 | −0.59±1.69 | −0.54 (−1.80, 0.72) | −0.63 (−2.07, 0.81) | −0.62 (−1.97, 0.74) | −0.76 (−2.34, 0.83) |
| Females (n=8) | −0.44±1.72 | 0.52±1.16 | 0.96 (−1.01, 2.93) | 0.27 (−3.09, 3.64) | 0.20 (−1.69, 2.09) | −0.83 (−3.85, 2.19) |
| Males (n=13) | 0.08±1.17 | −1.98±1.10 | ||||
|
| ||||||
|
| ||||||
| All | −0.30±0.80 | −0.25±0.91 | 0.05 (−0.57, 0.66) | 0.15 (−0.52, 0.82) | −0.02 (−0.69, 0.65) | −0.08 (−0.64, 0.80) |
| Females (n=14) | −0.65±0.59 | −0.02±1.04 | 0.62 (−0.37, 1.62) | 0.85 (−0.35, 2.05) | 0.70 (−0.48, 1.88) | 0.90 (−0.46, 2.27) |
| Males (n=16) | −0.12±0.86 | −0.60±0.58 | −0.47 (−1.25, 0.31) | −0.40 (−1.21, 0.41) | −0.59 (−1.42, 0.24) | −0.52 (−1.38, 0.34) |
|
| ||||||
|
| ||||||
| All | 2.6±0.3 | 2.5±0.5 | −0.13 (−0.42, 0.16) | −0.17(−0.48, 0.15) | −0.14 (−0.45, 0.18) | −0.18 (−0.52, 0.16) |
| Females (n=14) | 2.5±0.4 | 2.7±0.4 | 0.19 (−0.25, 0.63) | 0.09 (−0.43, 0.62) | 0.24 (−0.28, 0.76) | 0.15 (−0.45, 0.74) |
| Males (n=15) | 2.7±0.3 | 2.1±0.4 | ||||
|
| ||||||
| 4 (26.7) | 1 (6.7) | 0.27 (0.03, 2.39) | 0.27 (0.03, 2.76) | 0.26 (0.03, 2.72) | 0.26 (0.02, 3.42) | |
|
| ||||||
| 0 (0.0) | 1 (6.7) | – | – | – | – | |
|
| ||||||
|
| ||||||
| Head (growth measure) | 32.7±2.5 | 32.8±2.6 | 0.18 (−1.76, 2.12) | 0.16 (−1.93.,2.26) | −0.15 (−2.15, 1.86) | −0.19 (−2.37, 1.98) |
| Arm | 9.0±0.8 | 8.9±1.5 | −0.11 (−1.01, 0.80) | −0.19 (−1.16, 0.79) | −0.20 (−1.15, 0.75) | −0.30 (−1.32, 0.73) |
| Abdomen | 27.4±2.6 | 27.9±3.7 | 0.59 (−1.82, 2.99) | 0.56 (−2.04, 3.15) | 0.45 (−2.09, 3.00) | 0.41 (−2.35, 3.16) |
| Thigh | 13.4±1.3 | 13.4±2.7 | 0.03 (−1.56, 1.61) | −0.09 (−1.80, 1.61) | −0.30 (−1.91, 1.31) | −0.47 (−2.20, 1.27) |
|
| ||||||
|
| ||||||
| Triceps | 4.4±1.1 | 4.6±1.2 | 0.24 (−0.65, 1.12) | 0.01 (−0.90. 0.92) | 0.20 (−0.74, 1.14) | −0.04 (−1.01, 0.93) |
| Subscapular | 4.4±0.9 | 4.6±1.2 | 0.22 (−0.58, 1.01) | −0.08 (−0.86, 0.70) | 0.15 (−0.69, 0.99) | −0.17 (−1.00, 0.65) |
| Suprailiac | 4.0±1.0 | 4.0±1.0 | 0.03 (−0.70, 0.76) | −0.02 (−0.81, 0.76) | −0.002 (−0.775, 0.771) | −0.06 (−0.90, 0.77) |
| Thigh | 5.5±1.3 | 6.0±1.9 | 0.51 (−0.71, 1.73) | 0.29 (−1.00, 1.58) | 0.37 (−0.91, 1.64) | 0.12 (−1.23, 1.47) |
Notes: Bold italics highlight significant results. LGA is defined as birthweight <10th percentile or >90th percentile for GA, according to the WHO infant weight charts by gender in full-term newborns; GA adjustment was only performed for premature infants, who were evaluated using gender adjusted Fenton growth curves; Model 1 includes maternal age at baseline; Model 2 includes baseline maternal BMI status; Model 3 includes maternal age and BMI at baseline;
Median (Minimum, Maximum).
Abbreviations: BMI, body mass index; GA, gestational age; GWG, gestational weight gain; IOM, Institute of Medicine; LGA, large for GA; IRR, incidence rate ratio; SGA, small for GA; WFL, weight-for-length.
Description of daily energy and macronutrients intake across allocation groups and time points (N=17a)
| Energy/macronutrient | Time point | Control (n=11) | Intervention (n=6) |
|---|---|---|---|
|
| |||
| Mean ± SD/median (min, max) | Mean ± SD/median (min, max) | ||
|
| |||
| Total calorie intake (kcal/d) | Baseline | 2,445±956 | 2,644±1,100 |
| 36 weeks | 2,026±1,055 | 1,971±882 | |
| Change | −419±1,067 | −673±1,609 | |
| (median: −73, min: −2,729, max: 1,251) | (median: −115, min: −3,579, max: 694) | ||
| Protein (g/1,000 kcal) | Baseline | 37.2±4.3 | 33.6±5.1 |
| 36 weeks | 40.8±7.5 | 40.5±12.6 | |
| Change | 3.7±8.8 | 6.9±11.8 | |
| (median: 0.9, min: −5.3, max: 21.1) | (median: 4.8, min: −5.3, max: 27.1) | ||
| Fat (g/1,000 kcal) | Baseline | 38.3±5.1 | 36.6±2.4 |
| 36 weeks | 35.4±9.7 | 30.9±7.9 | |
| Change | −2.9±8.6 | −5.7±8.0 | |
| (median: −0.7, min: −12.5, max: 10.1) | (median: −6.8, min: −18.00, max: 3.5) | ||
| SFA (g/1,000 kcal) | Baseline | 13.3±2.5 | 12.2±1.5 |
| 36 weeks | 14.1±5.0 | 10.2±1.9 | |
| Change | 0.8±3.6 | −2.00±2.00 | |
| (median: 0.6, min: −4.4, max: 8.0) | (median: −2.2, min: −4.0, max: 0.8) | ||
| MFA (g/1,000 kcal) | Baseline | 14.0±1.9 | 13.3±1.2 |
| 36 weeks | 12.2±3.3 | 11.3±3.1 | |
| Change | −1.8±3.0 | −2.0±2.8 | |
| (median: −1.4, min: −5.7, max: 2.2) | (median: −2.2, min: −6.6, max: 1.1) | ||
| PUFA (g/1,000kcal) | Baseline | 8.0±1.2 | 8.1±2.3 |
| 36 weeks | 6.1±1.4 | 7.1±2.8 | |
| Change | −1.9±2.2 | −1.0±3.3 | |
| (median: −2.3, min: −5.4, max: 1.9) | (median: −1.1, min: −6.1, max: 2.9) | ||
| Carbohydrates (g/1,000 kcal) | Baseline | 126.6±13.7 | 136.1±4.8 |
| 36 weeks | 132.4±22.9 | 144.0±28.0 | |
| Change | 5.8±21.9 | 8.0±31.5 | |
| (median: 5.6, min: −26.8, max: 39.7) | (median: 5.6, min: −39.5, max: 52.4) | ||
| Fiber (g/1,000 kcal) | Baseline | 7.7±2.0 | 8.8±1.9 |
| 36 weeks | 7.9±2.3 | 11.8±4.1 | |
| Change | 0.1±2.4 | 3.0±2.6 | |
| (median: −0.3, min: −3.6, max: 3.8) | (median: 2.56, min: 0.046, max: 7.89) | ||
| Physical activity (n=15 | n=7 | n=8 | |
| Total physical activity | Baseline | 7,649.79±4,222.41 | 8,187.64±3,438.90 |
| 26–30 weeks | 4,471.10±3,530.27 | 5,428.70±4,076.79 | |
| Change | 3,178.69±4,792.87 | 2,758.94±4,573.06 | |
| (median: 4,968.45, min: −2,280.57, max: | (median: 3,949.87, min: −5,386.85, max: | ||
| 10,058.07) | 10,135.58) | ||
Notes: 26–30 weeks by ≥3 valid days.
Only participants who completed FFQs at baseline and 36 weeks and with a plausible energy intake (>1,075 kcal <4,800) were included in this analysis (33% of the participants delivered prematurely, hence 17 follow-up FFQs were available for comparison).
Participants who wore the accelerometer at baseline and 26–30 weeks by ≥3 valid days.
Mean VMU per minute from wrist-worn ActiGraph GT3X+.
Abbreviations: SFA, saturated fatty acids; MFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
Safety-related measures
| Incidence | Overall | Control | Intervention |
|---|---|---|---|
|
| |||
| Maternal | |||
| Gestational diabetes mellitus | 6 (19.4) | 3 (18.8) | 3 (20.0) |
| Preeclampsia | 7 (22.6) | 2 (12.5) | 5 (33.3) |
| Eclampsia | 2 (6.5) | 1 (6.3) | 1 (6.7) |
| Primary C-section | 14 (45.2) | 7 (43.8) | 7 (46.7) |
| Neonatal | |||
| NICU admissionb,c | 5 (16.1) | 2 (12.5) | 3 (20.0) |
| Prematurity (<37 weeks GA) | 10 (32.3) | 4 (25.0) | 6 (40.0) |
| Neonatal hypoglycemia | 4 (13.3) | 2 (13.3) | 2 (13.3) |
| Other complications | |||
| Birth trauma | 1 (3.3) | 0 (0.0) | 1 (6.7) |
| Respiratory morbidity | 4 (13.3) | 1 (6.7) | 3 (20.0) |
Notes: Medical diagnoses and adverse events abstracted from clinical records.
Screened between 24 and 27 weeks, diagnose based on the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria.
Denominator = number of pregnancies (N=31).
NICU: Admission to and stay in the Neonatal Intensive Care Unit or intermediate nursery (Level II) stay of at least 12 hours.
Newborn with low sugar levels that require intravenous glucose therapy.
One of several events occurring during birth, which results in damage to tissues or organs (including clavicular fracture, humerus fracture, skull fracture, brachial plexus injury, facial nerve injury, cephalohematoma and other qualifying traumas). One case of cephalohematoma reported.
Received treatment with supplemental O2 and CPAP or ventilator during the first 72 hours of life.
Abbreviations: GA, gestational age; CPAP, continuous positive airway pressure.
Sample size calculations (to achieve a power of 80% for the primary outcome, assuming a two-sided alpha of 0.05 and different proportions projected with adequate GWG)
| Outcome | Proportion in control | Proportion in experimental | N in each group |
|---|---|---|---|
|
| |||
| Weekly weight from baseline to 36 weeks | 0.19 | 0.25 | 748 |
| 0.19 | 0.27 | 434 | |
| 0.19 | 0.30 | 239 | |
| 0.19 | 0.35 | 120 | |
| 0.19 | 0.40 | 73 | |
| Weekly weight from baseline to delivery | 0.13 | 0.27 | 127 |
| Total weight from baseline until delivery | 0.25 | 0.40 | 152 |
Notes:
Proportion with adequate GWG (IOM guidelines) in PEARLS sample.
Projected with adequate GWG in PEARLS intervention group.
Abbreviations: GWG, gestational weight gain; IOM, Institute of Medicine; PEARLS, Pregnancy and EARly Lifestyle improvement Study.